# Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia

> **NCT03609593** · PHASE2 · COMPLETED · sponsor: **Nicole Lamanna** · enrollment: 42 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Bendamustine
- **DRUG:** Venetoclax
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03609593
- **Lead sponsor:** Nicole Lamanna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-12
- **Primary completion:** 2026-01-27
- **Final completion:** 2026-01-27
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03609593

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03609593, "Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03609593. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*